

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute, and is not intended to be, an invitation or offer to acquire, purchase or subscribe for, or offer to sell or a solicitation of any offer to buy securities in Hong Kong, the PRC or elsewhere.



Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

INSIDE INFORMATION PRE-LISTING TUTORING APPLICATION

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 7 April 2024, the Company submitted an application to the Shanghai Regulatory Bureau of the China Securities Regulatory Commission for the filing of an application for pre-listing tutoring.

The Company intends to prepare for a listing in the stock exchange in the People's Republic of China (the “**PRC**”) (the “**Proposed A Share Listing**”) due to its business development. China International Capital Corporation acts as the tutoring institution in relation to the Proposed A Share Listing. The Proposed A Share Listing is still in its early preparation stage. As at the date of this announcement, the Company has not submitted any official application for listing to any relevant regulatory authorities in the PRC.

The Proposed A Share Listing is also subject to approval or clearance by regulatory authorities including the China Securities Regulatory Commission, the relevant stock exchange in the PRC and The Stock Exchange of Hong Kong Limited, and there exists uncertainty as to whether the Proposed A Share Listing will ultimately be approved or the timing of such approval. The Company will strictly comply with the requirements of relevant laws, regulations, departmental rules and regulatory documents and will fulfill its information disclosure obligations in a timely manner according to the progress of the Proposed A Share Listing.

Shareholders and potential investors of the Company are advised to note that the Proposed A Share Listing is, among others, subject to market conditions, approvals from relevant authorities (including but not limited to the China Securities Regulatory Commission, the relevant stock exchange in the PRC and The Stock Exchange of Hong Kong Limited) and the final decision made by the Company. As such, there is no assurance as to whether and when the Proposed A Share Listing will take place or complete. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the People's Republic of China
7 April 2024

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Mr. Zhang Weixin, Ms. Chen Hongqin, Dr. Song Yuan and Mr. Wang Ruiqin as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*